Repare Therapeutics shares are trading lower after Roche terminated cancer drug deal and the company regained global rights to camonsertib.
Portfolio Pulse from Benzinga Newsdesk
Repare Therapeutics' stock is trading lower following the termination of a cancer drug deal with Roche, resulting in Repare regaining global rights to camonsertib.
February 13, 2024 | 1:40 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Repare Therapeutics' shares have declined after Roche terminated their cancer drug partnership, returning global rights of camonsertib to Repare.
The termination of the deal with Roche, a major pharmaceutical company, is likely seen as a negative development for Repare Therapeutics. Losing a partnership with a company of Roche's stature could raise concerns about the potential of camonsertib and impact investor confidence, leading to a short-term decline in RPTX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100